AVALO THERAPEUTICS, INC. Derivative Liability
AVALO THERAPEUTICS, INC. (AVTX) had Derivative Liability of $18.53 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2026-08-06
- 2026-06-30: Derivative Liability $18.53M.
- 2026-03-31: Derivative Liability $17.52M.
- 2025-12-31: Derivative Liability $18.00M.
- 2024-12-31: Derivative Liability $8.48M.
| Period end | Derivative Liability |
|---|---|
| 2026-06-30 | $18.53M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $17.52M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $18.00M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $8.48M 10-K · filed 2026-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |